Skip to main content
Journal cover image

Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.

Publication ,  Journal Article
Koontz, BF; Miles, EF; Rubio, MAD; Madden, JF; Fisher, SR; Scher, RL; Brizel, DM
Published in: Head Neck
February 2008

BACKGROUND: Angiosarcoma of the face is a vascular tumor with poor local control and short median survival despite standard treatment. Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), which can inhibit tumor growth. It is synergistic with radiotherapy in gastrointestinal malignancies. Given the vascular nature of angiosarcoma and the need for better treatment of this disease, we investigated the concurrent use of bevacizumab with preoperative radiotherapy for head and neck angiosarcoma. METHODS: Two patients diagnosed with angiosarcoma of the nose were treated preoperatively with bevacizumab (5-10 mg/kg) and concurrent radiotherapy (50 Gy), followed by resection of the tumor bed. RESULTS: Both patients had a complete pathologic response with no residual disease. Neither has developed recurrence, with follow-up of 8.5 months and 2.1 years. CONCLUSIONS: The neoadjuvant combination of bevacizumab and radiation therapy is promising and should be further studied in the setting of vascular malignancies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Head Neck

DOI

ISSN

1043-3074

Publication Date

February 2008

Volume

30

Issue

2

Start / End Page

262 / 266

Location

United States

Related Subject Headings

  • Radiotherapy Dosage
  • Otorhinolaryngology
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Humans
  • Hemangiosarcoma
  • Head and Neck Neoplasms
  • Combined Modality Therapy
  • Chemotherapy, Adjuvant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Koontz, B. F., Miles, E. F., Rubio, M. A. D., Madden, J. F., Fisher, S. R., Scher, R. L., & Brizel, D. M. (2008). Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck, 30(2), 262–266. https://doi.org/10.1002/hed.20674
Koontz, Bridget F., Edward F. Miles, Mary Ann D. Rubio, John F. Madden, Samuel R. Fisher, Richard L. Scher, and David M. Brizel. “Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.Head Neck 30, no. 2 (February 2008): 262–66. https://doi.org/10.1002/hed.20674.
Koontz BF, Miles EF, Rubio MAD, Madden JF, Fisher SR, Scher RL, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008 Feb;30(2):262–6.
Koontz, Bridget F., et al. “Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.Head Neck, vol. 30, no. 2, Feb. 2008, pp. 262–66. Pubmed, doi:10.1002/hed.20674.
Koontz BF, Miles EF, Rubio MAD, Madden JF, Fisher SR, Scher RL, Brizel DM. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck. 2008 Feb;30(2):262–266.
Journal cover image

Published In

Head Neck

DOI

ISSN

1043-3074

Publication Date

February 2008

Volume

30

Issue

2

Start / End Page

262 / 266

Location

United States

Related Subject Headings

  • Radiotherapy Dosage
  • Otorhinolaryngology
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Humans
  • Hemangiosarcoma
  • Head and Neck Neoplasms
  • Combined Modality Therapy
  • Chemotherapy, Adjuvant